Cencora (NYSE:COR) Price Target Raised to $419.00

Cencora (NYSE:COR) had its target price upped by JPMorgan Chase & Co. from $417.00 to $419.00 in a report published on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other analysts have also issued reports on the stock. Bank of America lowered their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. UBS Group upped their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Wells Fargo & Company raised their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $396.92.

Cencora Stock Performance

Cencora stock opened at $351.91 on Tuesday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The firm has a market capitalization of $68.27 billion, a P/E ratio of 42.30, a price-to-earnings-growth ratio of 1.69 and a beta of 0.68. Cencora has a 1-year low of $237.71 and a 1-year high of $377.54. The company’s 50-day moving average is $347.08 and its 200 day moving average is $327.83.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the firm posted $3.73 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. Research analysts forecast that Cencora will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is 28.85%.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is currently owned by corporate insiders.

Institutional Trading of Cencora

A number of institutional investors have recently modified their holdings of the company. Vestcor Inc lifted its position in Cencora by 0.5% during the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after acquiring an additional 28 shares during the last quarter. JFS Wealth Advisors LLC lifted its holdings in shares of Cencora by 30.2% during the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after purchasing an additional 29 shares during the last quarter. Cornerstone Wealth Group LLC boosted its position in shares of Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after purchasing an additional 30 shares in the last quarter. Apollon Wealth Management LLC grew its stake in Cencora by 0.5% during the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock worth $2,205,000 after buying an additional 30 shares during the last quarter. Finally, Accent Capital Management LLC increased its position in Cencora by 36.1% during the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after buying an additional 30 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.